Editorial comment on: Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam).
作者信息
Terris Martha K
出版信息
Eur Urol. 2009 Feb;55(2):392; discussion 393. doi: 10.1016/j.eururo.2008.02.047. Epub 2008 Mar 11.
PMID:18353530
Abstract
摘要
相似文献
1
Editorial comment on: Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam).
Eur Urol. 2009 Feb;55(2):392; discussion 393. doi: 10.1016/j.eururo.2008.02.047. Epub 2008 Mar 11.
2
Cost-effectiveness of prostate specific antigen screening in the United States: extrapolating from the European study of screening for prostate cancer.
J Urol. 2011 Mar;185(3):828-32. doi: 10.1016/j.juro.2010.10.079. Epub 2011 Jan 15.
3
Rural residence and prostate cancer screening with prostate-specific antigen.
Rural Remote Health. 2009 Apr-Jun;9(2):1227. Epub 2009 Jun 18.
4
Screening for prostate cancer.
J Fam Pract. 1999 Aug;48(8):581-2.
5
Efficacy vs effectiveness in prostate-specific antigen screening.
J Natl Cancer Inst. 2010 Mar 3;102(5):288-9. doi: 10.1093/jnci/djq002. Epub 2010 Feb 8.
6
Randomized trial results did not resolve controversies surrounding prostate cancer screening.
Curr Opin Urol. 2010 May;20(3):189-93. doi: 10.1097/MOU.0b013e3283383b55.
7
Defining increased future risk for prostate cancer: evidence from a population based screening cohort.
J Urol. 2009 Jan;181(1):69-74; discussion 74. doi: 10.1016/j.juro.2008.09.012. Epub 2008 Nov 13.
8
Prostate specific antigen and screening for early prostate cancer.
N Z Med J. 2001 Apr 13;114(1129):150.
9
Prostate-specific antigen: a new(ish) study.
Harv Mens Health Watch. 2010 Nov;15(4):6-8.
10
Rotterdam randomized pilot studies of screening for prostate cancer--an overview after 10 years.
J Natl Cancer Inst. 2005 May 4;97(9):696. doi: 10.1093/jnci/dji121.
Zotero 插件